PDCD1 and skin squamous cell carcinoma: Cemiplimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), has demonstrated high efficacy in treating advanced cSCC, with objective response rates (ORR) ranging from 32% to 77% in various studies (196).